- Conditions
- Prostate Cancer
- Interventions
- Taxotere, Celecoxib
- Drug
- Lead sponsor
- Department of Veterans Affairs, New Jersey
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- East Orange, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2665–2688
of 12,573
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis 1 (NF1)
- Interventions
- mirdametinib with radiation, mirdametinib
- Combination Product · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years to 89 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Melanoma
- Interventions
- PVSRIPO, Nivolumab
- Biological · Drug
- Lead sponsor
- Darell Bigner
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Photoaging, Wrinkle, Sun Damaged Skin
- Interventions
- Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
- Combination Product
- Lead sponsor
- Vitality Institute Medical Products
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rancho Mirage, California
- Conditions
- Osteoarthritis, Knee
- Interventions
- Diclofenac, topical
- Drug
- Lead sponsor
- Nuvo Research Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2, Impaired Renal Function
- Interventions
- Dapagliflozin 10 MG [Farxiga]
- Drug
- Lead sponsor
- Emerald Clinical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Ibrutinib, Rituximab, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Rochester, Minnesota + 7 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Lumiliximab + FCR, FCR
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- HIV Infections
- Interventions
- Low dose Kaletra tablets
- Drug
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Transgender Women
- Interventions
- Placebo, Progesterone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Asthma
- Interventions
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Boerne, Texas
- Conditions
- Medical Oncology
- Interventions
- BAY1143269 tablet
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Houston, Texas • San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Observation
- Other
- Lead sponsor
- BioCorteX Inc
- Industry
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Decatur, Illinois • Las Vegas, Nevada • Belleville, New Jersey + 3 more
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- KX2-391
- Drug
- Lead sponsor
- Athenex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Small Cell Lung Cancer
- Interventions
- Carboplatin, Placebo, Trilaciclib, Etoposide
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Rogers, Arkansas • Whittier, California + 22 more
- Conditions
- Small Cell Lung Cancer, Ovarian Cancer
- Interventions
- LCL161, Topotecan, Pegylated GCSF (PEG-GCSF)
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Influenza, Healthy Volunteers
- Interventions
- Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
- Conditions
- Heart Failure, Cancer Treatment Induced Left Ventricular Dysfunction
- Interventions
- Echocardiograms, Electrocardiogram, Symptom Questionnaire, Telephone Follow-Up
- Device · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sacituzumab Govitecan, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
- Conditions
- Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Flt3L, Radiation, Poly ICLC
- Drug · Radiation
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
- Interventions
- CB-839, Talazoparib
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- filgrastim, carboplatin, gemcitabine hydrochloride, ifosfamide, paclitaxel, adjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine, Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida